Home » Topics » BioWorld Science

BioWorld Science
RSS

Targeted protein degradation with DGY-08-097 shows promise for hepatitis C virus treatment

Sep. 4, 2019

Boehringer Ingelheim to advance BI-456906 into phase II for obesity and diabetes

Sep. 3, 2019

Grunenthal and UniQuest establish neuropathic pain collaboration

Sep. 3, 2019

Twinrab approved in India for rabies

Sep. 3, 2019

FDA approves Kuros' IND for phase IIa trial of KUR-113 for spinal fusion

Sep. 3, 2019

ObsEva reports mechanism-of-action data on oxytocin receptor antagonist nolasiban

Sep. 3, 2019

Suven evaluates SUVN-G3031 in phase II trial for narcolepsy with and without cataplexy

Sep. 3, 2019

eXIthera Pharmaceuticals divulges coagulation factor XIa and kallikrein inhibitors

Sep. 3, 2019

Eli Lilly and Company describes PDE1 inhibitors

Sep. 3, 2019

Crinetics Pharmaceuticals identifies somatostatin SST5 receptor agonists

Sep. 3, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...